EHS partners with Novo Nordisk Pharma Gulf to provide treatment to patients with Type 2 diabetes

EHS partners with Novo Nordisk Pharma Gulf to provide treatment to patients with Type 2 diabetes

Emirates Health Services (EHS) and Novo Nordisk Pharma Gulf will collaborate on areas of common interest, most notably healthcare innovation, following the signing of a memorandum of understanding (MoU), in a bid to enhance health services and implement the most advanced medical breakthroughs.

The MoU was signed by Dr. Yousif Mohammed Al Serkal, Director-General of EHS, and Mads Bo Larsen, Vice President and General Manager of Novo Nordisk Pharma Gulf.

Under the terms of the MoU, Novo Nordisk Pharma Gulf pledges to provide 12 months of free treatment with its oral Semaglutide drug for 50 patients with Type 2 diabetes. Therapeutic outcomes are set to be evaluated by EHS within six months. The company will also provide support through scientific communication treating physicians on the management of type 2 diabetes.

Furthermore, the agreement aims to ensure coordination between the two entities through consistent communication between healthcare providers at EHS, on one hand, and medical directors and specialists at Novo Nordisk Pharma Gulf, on the other, to provide guidance on diabetes treatment. To that end, the company will provide EHS with up-to-date global and local algorithms for diabetes treatment.

The two entities will also collaborate on educational programmes and panel discussions for healthcare providers at hospitals and healthcare centres under the EHS umbrella that offer diabetes treatments.

"Signing this MoU with Novo Nordisk Pharma Gulf is in line with our objectives at Emirates Health Services to provide innovative and sustainable health services, enhance the efficiency of the health system as a whole, and position the sector as a leader in providing world-class healthcare that is up to the highest standards and meets every requirement of patients and customers,"

Dr. Al Serkal said.

Mads Bo Larsen commented,

"At Novo Nordisk Pharma Gulf, we constantly strive to be part of initiatives that offer care for diabetes patients in the UAE. With that in mind, we are proud of the integrated and effective coordination we have established with Emirates Health Services on these initiatives, which form part of EHS’ efforts to develop and implement innovative healthcare solutions that meet the requirements and standards of the future."

News Source: Emirates News Agency

- Advertisement -
Dark Light